BETHESDA, Md., Aug. 6 /PRNewswire-USNewswire/ — The U.S. Senate last night passed the “Improving Access to Clinical Trials Act” (I-ACT), a bipartisan piece of legislation championed by the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.
The legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits.
